文献リスト

1) Parsons JK, Carter HB, Platz EA, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2257-60

2) Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate car-cinoma: a longitudinal study. Cancer. 1999; 86: 312-5

3) Gann PH, Hennekens CH, Ma J, et al. Pro-spective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996; 88: 1118-26

4) Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subse-quent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993; 2: 27-32

5) Guess HA, Friedman GD, Sadler MC, et al. 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomarkers Prev. 1997; 6: 21-4

6) Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997; 6: 967-9

7) Dorgan JF, Albanes D, Virtamo J, et al. Relation-ships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998; 7: 1069 -74

8) Eaton NE, Reeves GK, Appleby PN, et al. En-dogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999; 80: 930-4

9) Nomura AM, Stemmermann GN, Chyou PH, et al. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996; 5: 621-5

10) Fears TR, Ziegler RG, Donaldson JL, et al. Reproducibility studies and interlaboratory con-cordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev. 2000; 9: 403-12

11) Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-I, body size and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis. 2000; 3: 157-72

12) Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002; 3: 565-74

13) Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003; 348: 1625-38

14) Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U. S. Health professionals. J Natl Cancer Inst. 2003; 95: 1240-4

15) Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998; 58: 4497-504

16) Ross RK, Bernstein L, Lobo RA, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992; 339: 887-9

17) Statin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004; 108: 418-24

18) Hsing AW. Hormones and prostate cancer: what's next？ Epidemiol Rev. 2001; 23: 42-58

19) Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004; 350: 482-92

20) Bhasin S, Singh AB, Mac RP, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recom-mendations for a standardized monitoring plan. J Androl. 2003; 24: 299-311

21) Barqawi AB, Crawford ED. Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int J Impot Res. 2005; 17: 462-3

22) Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4. 0 ng/ml or less. Urology. 2006; 68: 1263-7

23) Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ＜ or＝4. 0 ng per milliliter. N Engl J Med. 2004; 350: 2239-46

24) Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999; 59: 4161-4

25) Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer？ J Urol. 2000; 163: 824-7

26) Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001; 47: 52-8

27) Yano M, Imamoto T, Suzuki H, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007; 51: 293-5

28) Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol. 1997; 20: 605-8

29) Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical pros-tatectomy. J Urol. 2003; 169: 1670-5

30) Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol. 2005; 47: 308-12

31) Isom-Batz G, Bianco Jr FJ, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005; 173: 1935-7

32) Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006; 50: 935-9

33) Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1262-9

34) Zhang PL, Rosen S, Veeramachaneni R, et al. Association between prostate cancer and serum testosterone levels. Prostate. 2002; 53: 179-82

35) Teloken C, Da Ros CT, Caraver F, et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005; 174: 2178-80

36) Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical retropubic pros-tatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993; 20: 713-25

37) Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28: 555-65

38) Iversen P, Rasmussen F, Christensen IJ. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl. 1994; 157: 41-7

39) Miller LR, Partin AW, Chan DW, et al. Influence of radical prostatectomy on serum hormone levels. J Urol. 1998; 160: 449-53

40) Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 1999; 59: 4161-4

41) Imamoto T, Suzuki H, Yano M, et al. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients？ Prostate Cancer and Prostatic Diseases. 2008; in press

42) Lukkarinen O, Hammond GL, Kontturi M, et al. Peripheral and prostatic vein steroid concen-trations in benign prostatic hypertrophy patients before and after removal of the adenoma. Scand J Urol Nephrol. 1980; 14: 225-7

43) Madersbacher S, Schatzl G, Bieglmayer C, et al. Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis. Urology. 2002; 60: 869-74

44) Phadke MA, Vanage GR, Sheth AR. Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection. Prostate. 1987; 10: 115-22

45) Lokeshwar BL, Hurkadli KS, Sheth AR, et al. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res. 1993; 53: 4855-9

46) Sheth AR, Garde SV, Mehta MK, et al. Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. Indian J Exp Biol. 1992; 30: 157-61

47) Risbridger GP, Shibata A, Ferguson KL, et al. Elevated expression of inhibin a in prostate cancer. J Urol. 2004; 171: 192-6

48) Yamamoto S, Yonese J, Kawakami S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007; 52: 696-701

49) Morgentaler A, Bruning III CO, DeWolf WC. Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA. 1996; 276: 1904-6

50) Imamoto T, Suzuki H, Akakura K, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J. 2001; 48: 573-8

51) Chodak GW, Vogelzang NJ, Caplan RJ, et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA. 1991; 265: 618-21

52) Jorgensen T, Kanagasingam Y, Kaalhus O, et al. Prognostic factors in patients with metastatic (stage D2) prostate cancer: Experience from the Scandinavian prostatic cancer group study-2. J Urol. 1997; 158: 164-70

53) Chen SS, Chen KK, Lin AT, et al. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int. 2002; 89: 710-3

54) Nishiyama T, Ikarashi T, Hashimoto Y, et al. Association between the dihydrotestosterone level in the prostate and prostate cancer aggres-siveness using the Gleason score. J Urol. 2006; 176: 1387-91

55) Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005; 23: 7546-54

56) Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst. 2000; 27: 67-73

57) Irani J, Ravery V, Pariente JL, et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol. 2002; 168: 1985-8

58) Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997; 94: 3320-3

59) Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006; 296: 2351-61

60) Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001; 281: 1172-81

61) Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000; 85: 2670-7

62) Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001; 56: 266-72

63) Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84: 1966-72

64) Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997; 82: 1661-7

65) Dobs AS, Meikle AW, Arver S, et al. Phar-macokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999; 84: 3469-78

66) Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000; 85: 2839-53

67) Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002; 87: 136-43

68) Cooper CS, Perry PJ, Sparks AET, et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998; 159: 441-3

69) Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003; 170: 2348-51

70) Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical cha-racteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006; 18: 201-5

71) Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007; 109: 536-41

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp